These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 31901375)

  • 1. Outer membrane vesicle increases the efficacy of an influenza vaccine in a diet-induced obese mouse model.
    Lee TY; Kim CU; Lee P; Seo SH; Bae EH; Kim YS; Kim SH; Kim DJ
    Immunol Lett; 2020 Mar; 219():27-33. PubMed ID: 31901375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outer membrane vesicles harboring modified lipid A moiety augment the efficacy of an influenza vaccine exhibiting reduced endotoxicity in a mouse model.
    Lee TY; Kim CU; Bae EH; Seo SH; Jeong DG; Yoon SW; Chang KT; Kim YS; Kim SH; Kim DJ
    Vaccine; 2017 Jan; 35(4):586-595. PubMed ID: 28024958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nontoxic outer membrane vesicles efficiently increase the efficacy of an influenza vaccine in mice and ferrets.
    Shim SM; Song EJ; Song D; Lee TY; Kim DJ; Nam JH; Gwin Jeong D; Lee CK; Kim SH; Kim JK
    Vaccine; 2017 Jun; 35(30):3741-3748. PubMed ID: 28576571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant H5 hemagglutinin adjuvanted with nanoemulsion protects ferrets against pathogenic avian influenza virus challenge.
    Wang SH; Smith D; Cao Z; Chen J; Acosta H; Chichester JA; Yusibov V; Streatfield SJ; Fattom A; Baker JR
    Vaccine; 2019 Mar; 37(12):1591-1600. PubMed ID: 30795941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthetic Toll-Like Receptor 4 (TLR4) and TLR7 Ligands Work Additively via MyD88 To Induce Protective Antiviral Immunity in Mice.
    Goff PH; Hayashi T; He W; Yao S; Cottam HB; Tan GS; Crain B; Krammer F; Messer K; Pu M; Carson DA; Palese P; Corr M
    J Virol; 2017 Oct; 91(19):. PubMed ID: 28724768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced Influenza Virus-Like Particle Vaccination with a Structurally Optimized RIG-I Agonist as Adjuvant.
    Beljanski V; Chiang C; Kirchenbaum GA; Olagnier D; Bloom CE; Wong T; Haddad EK; Trautmann L; Ross TM; Hiscott J
    J Virol; 2015 Oct; 89(20):10612-24. PubMed ID: 26269188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safe Recombinant Outer Membrane Vesicles that Display M2e Elicit Heterologous Influenza Protection.
    Watkins HC; Rappazzo CG; Higgins JS; Sun X; Brock N; Chau A; Misra A; Cannizzo JPB; King MR; Maines TR; Leifer CA; Whittaker GR; DeLisa MP; Putnam D
    Mol Ther; 2017 Apr; 25(4):989-1002. PubMed ID: 28215994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intranasal Immunization with Influenza Virus-Like Particles Containing Membrane-Anchored Cholera Toxin B or Ricin Toxin B Enhances Adaptive Immune Responses and Protection against an Antigenically Distinct Virus.
    Ji X; Ren Z; Xu N; Meng L; Yu Z; Feng N; Sang X; Li S; Li Y; Wang T; Zhao Y; Wang H; Zheng X; Jin H; Li N; Yang S; Cao J; Liu W; Gao Y; Xia X
    Viruses; 2016 Apr; 8(4):115. PubMed ID: 27110810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant use of the NKT cell agonist alpha-galactosylceramide leads to enhancement of M2-based DNA vaccine immunogenicity and protective immunity against influenza A virus.
    Fotouhi F; Shaffifar M; Farahmand B; Shirian S; Saeidi M; Tabarraei A; Gorji A; Ghaemi A
    Arch Virol; 2017 May; 162(5):1251-1260. PubMed ID: 28120096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An Improved Inactivated Influenza Vaccine with Enhanced Cross Protection.
    Ni Y; Guo J; Turner D; Tizard I
    Front Immunol; 2018; 9():1815. PubMed ID: 30140267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthetic Toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained, and broadly protective responses.
    Goff PH; Hayashi T; Martínez-Gil L; Corr M; Crain B; Yao S; Cottam HB; Chan M; Ramos I; Eggink D; Heshmati M; Krammer F; Messer K; Pu M; Fernandez-Sesma A; Palese P; Carson DA
    J Virol; 2015 Mar; 89(6):3221-35. PubMed ID: 25568203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A cationic liposome-DNA complexes adjuvant (JVRS-100) enhances the immunogenicity and cross-protective efficacy of pre-pandemic influenza A (H5N1) vaccine in ferrets.
    Liu F; Sun X; Fairman J; Lewis DB; Katz JM; Levine M; Tumpey TM; Lu X
    Virology; 2016 May; 492():197-203. PubMed ID: 26967975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody responses and protection against influenza virus infection in different congenic strains of mice immunized intranasally with adjuvant-combined A/Beijing/262/95 (H1N1) virus hemagglutinin or neuraminidase.
    Yoshikawa T; Suzuki Y; Nomoto A; Sata T; Kurata T; Tamura Si
    Vaccine; 2002 Nov; 21(1-2):60-6. PubMed ID: 12443663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diet-induced obesity dramatically reduces the efficacy of a 2009 pandemic H1N1 vaccine in a mouse model.
    Kim YH; Kim JK; Kim DJ; Nam JH; Shim SM; Choi YK; Lee CH; Poo H
    J Infect Dis; 2012 Jan; 205(2):244-51. PubMed ID: 22147801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cross-Protective Immune Responses Induced by Sequential Influenza Virus Infection and by Sequential Vaccination With Inactivated Influenza Vaccines.
    Dong W; Bhide Y; Sicca F; Meijerhof T; Guilfoyle K; Engelhardt OG; Boon L; de Haan CAM; Carnell G; Temperton N; de Vries-Idema J; Kelvin D; Huckriede A
    Front Immunol; 2018; 9():2312. PubMed ID: 30356772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influenza Virus Hemagglutinin Stalk-Specific Antibodies in Human Serum are a Surrogate Marker for
    Jacobsen H; Rajendran M; Choi A; Sjursen H; Brokstad KA; Cox RJ; Palese P; Krammer F; Nachbagauer R
    mBio; 2017 Sep; 8(5):. PubMed ID: 28928215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mini-HA Is Superior to Full Length Hemagglutinin Immunization in Inducing Stem-Specific Antibodies and Protection Against Group 1 Influenza Virus Challenges in Mice.
    van der Lubbe JEM; Verspuij JWA; Huizingh J; Schmit-Tillemans SPR; Tolboom JTBM; Dekking LEHA; Kwaks T; Brandenburg B; Meijberg W; Zahn RC; Roozendaal R; Kuipers H
    Front Immunol; 2018; 9():2350. PubMed ID: 30369928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generation of DelNS1 Influenza Viruses: a Strategy for Optimizing Live Attenuated Influenza Vaccines.
    Wang P; Zheng M; Lau SY; Chen P; Mok BW; Liu S; Liu H; Huang X; Cremin CJ; Song W; Chen Y; Wong YC; Huang H; To KK; Chen Z; Xia N; Yuen KY; Chen H
    mBio; 2019 Sep; 10(5):. PubMed ID: 31530680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of Broad-Based Immunity and Protective Efficacy by Self-amplifying mRNA Vaccines Encoding Influenza Virus Hemagglutinin.
    Brazzoli M; Magini D; Bonci A; Buccato S; Giovani C; Kratzer R; Zurli V; Mangiavacchi S; Casini D; Brito LM; De Gregorio E; Mason PW; Ulmer JB; Geall AJ; Bertholet S
    J Virol; 2016 Jan; 90(1):332-44. PubMed ID: 26468547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intranasal immunization with live attenuated influenza vaccine plus chitosan as an adjuvant protects mice against homologous and heterologous virus challenge.
    Wang X; Zhang W; Liu F; Zheng M; Zheng D; Zhang T; Yi Y; Ding Y; Luo J; Dai C; Wang H; Sun B; Chen Z
    Arch Virol; 2012 Aug; 157(8):1451-61. PubMed ID: 22552485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.